Institution Cancer Research Center of Toulouse (CRCT)
UMR1037 INSERM/CNRS/Université Toulouse III- Team 17
Contacts julie.guillermet@inserm.fr

Dr Guillermet-Guibert leads a group on PI3K signalling in pancreatic cancer in the new comprehensive Cancer Research Center INSERM UMR1037 recently created in Toulouse, France.
She studied at the Ecole Normale Supérieure de Lyon, France, and carried out Ph.D. work on somatostatin G protein-coupled receptor signalling in pancreatic cancer at the University of Toulouse, France / INSERM Laboratory. In 2005, she undertook postdoctoral research in the laboratory of Prof. B. Vanhaesebroeck, Ludwig Institute for Cancer Research, now in UCL, London, UK. During this post-doctoral training, she authored two highly cited original research papers, both reviewed in F1000 and Hot papers of the year in ISIWeb of Science. In 2010, she was appointed as a researcher at INSERM Toulouse.

Interest of the group:
The group focus its attention on a family of crucial signal transduction enzymes PI3Ks. Across species, the dogma for their involvement in cell signalling is the following: after acute stimulation, PI3K phosphorylates the lipid second messenger phosphatidylinositol 4,5-biphosphate into PI-3,4,5-triphosphate (PIP3) at the plasma membrane, further activating the protein kinases Akt and mTOR, and regulating crucial cell biology events such as cell proliferation and protein synthesis. This signalling axis called PI3K/Akt/mTOR is altered in cancers, constituting an excellent new therapeutic target in this pathology. But, in mammals, 1- PIP3 producing PI3K activity in itself is separated into 4 isoforms which are physiologically functionally non redundant (Vanhaesebroeck, Guillermet-Guibert Nature MCB 2010 PMID: 20379207), and 2- there is more than PI3K/Akt/mTOR pathway, other signalling routes being integral part of the isoform-specific in vivo role of mammals PI3Ks, in particular in cancer cell settings. This program is mainly based on the use of robust and unique genetic mouse models, which mimic pharmacological intervention.

Prestigious European fundings:
Beneficiary of 2 Marie-Curie actions under FP6/7-Funding scheme (EIF 2006: The role of p110beta isoform of PI 3-kinase in endothelial cells and angiogenesis, ERG 2011: Characterisation of PI3K isoform roles in pancreatic cancerogenesis).

Other prestigious grants include: EMBO-LTF(2005), French training Normalienne-ENSLyon.

Key words:       mouse genetics, cell signaling, PI3K, cancer, drug resistance
ISI-Web of Science-ResearcherID or ORCID ID:        D-2317-2014
Scopus Author ID:       8847067100

Work Group: Translation Research (wg3)